Navigation Links
Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston
Date:5/12/2009

SAN CARLOS, Calif., May 12 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) is scheduled to present at the upcoming Deutsche Bank 34th Annual Health Care Conference in Boston at the Boston InterContinental Hotel on Monday, May 18, 2009 at 1:45 p.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until June 10, 2009.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. For more information on Nektar Therapeutics, please visit http://www.nektar.com.

    Nektar Contacts:

    Jennifer Ruddock
    Nektar Therapeutics
    650-631-4954
    jruddock@nektar.com

    Susan Noonan
    The SAN Group
    212-966-3650
    susan@sanoonan.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
2. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
3. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
4. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
6. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
8. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
9. Nektar Therapeutics Announces First Quarter 2008 Results
10. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
11. Nektar Therapeutics Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... Mother Nature isn’t the only mom ... fruits and vegetables. , Celebrate these women with more than just a bouquet ... with these five garden-themed options. , Vibrant, Edible, Compact Plants from BrazelBerries: , ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... to identify, fund and implement ideas aimed at improving care and reducing readmission ... “Part of our vision for Trinity Health is to drive innovation that transforms ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... and Vancouver, WA, has announced the latest beneficiary of their ongoing community ... and their Mammography Program, which provides free mammograms and diagnostic breast care ...
(Date:5/4/2016)... ... May 04, 2016 , ... The ... research and development of DRACO broad-spectrum antiviral therapeutics. DRACOs have proven effective against ... on May 3, 2016 at http://igg.me/at/EndTheVirus and runs for 60 days, ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nike Rugby Camp's success is due in ... Willis, founder of Elite Rugby Camps and current Nike Camp director, has offered an ... 2009. , “I’m excited for our eighth summer here in San Diego,” says ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)...  It,s time for an upgrade. There are many medical recorders on the market ... the illustrious DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a renowned ... manufacturer of innovative technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... BRIDGEWATER, New Jersey , May 4, 2016 /PRNewswire/ ... today its successful completion of an alternative public offering ... its wholly owned operating company, Valeritas, Inc. and a ... unregistered common stock at $5.00 per share. ... completed on May 3, 2016, Valeritas Holdings, Inc. will ...
(Date:5/4/2016)... Research and Markets has ... lymphocytic Leukemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights 2016, provides comprehensive ... Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic Leukemia ...
Breaking Medicine Technology: